Scientific Company Directory

NanoString Technologies (NASDAQ: NSTG) is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications. NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer. Organizations performing cancer research, biomarker validation and screening, and next-generation sequencing validation are rapidly adopting the nCounter® Analysis System. By providing simple, multiplexed digital profiling of single molecules, the NanoString platform represents a natural, digital downstream companion to next-generation sequencing and enables researchers to embark on studies that were previously inconceivable. Leading researchers and institutions are finding that NanoString's nCounter system provides the ideal platform on which to validate their discoveries and translate them into clinically useful diagnostic assays. The nCounter system is uniquely positioned to support translational research because it provides more reproducible results than methods requiring amplification, and generates high-quality data from the difficult sample types common in clinical research, including Formalin-Fixed Paraffin-Embedded (FFPE) tissues. In addition to continuing to extend the applications for the nCounter system in the discovery, target validation and routine testing segments of the genomics research market, the company's goal is to become the platform of choice for diagnostic testing based on multiplexed gene signatures that can be offered in hospitals and pathology laboratories worldwide, following appropriate regulatory approvals. These two synergistic areas of business focus provide researchers with a seamless transition from discovery to diagnostics.

NanoCellect is committed to empowering every scientist to make discoveries one cell at a time, with modern and simple technologies for cell based assays. Our microfluidic flow cytometry platforms enable biomedical scientists to analyze and sort cells required for drug discovery, diagnostics, and basic research. The company was founded in late 2009 as a spinout from UCSD and dedicated 6 years developing the foundation of the WOLF's technology before introducing the WOLF to early adopters. Initial funding of R&D was graciously funded by multiple NIH SBIR grants and contracts. We are backed by Illumina Ventures, FusionX Ventures, Anzu Partners, Agilent Technologies, Vertical Ventures (Highlander Fund and Triton Fund) and other private investors.

Next Advance, Inc. develops and sells innovative, high-value, user-friendly laboratory instruments for molecular biologists. Designed and tested by our multi-disciplined cross-trained staff, our products automate mundane tasks, freeing scientists from repetitive, time-consuming procedures.

NMI TT Pharmaservices is an established provider of non-clinical contract research for protein profiling services, custom cell services, and electrophysiology services. The company has a long-standing CRO track record with numerous small, medium and large pharma and biotech companies worldwide. The services are accessible through direct contracts or Master Service Agreements (MSAs), or immediately via online marketplaces Scientist.com and ScienceExchange.

NanoTemper Technologies is deeply committed to the best customer experience. Central to this is a strong focus on enabling researchers to easily, efficiently, and accurately perform protein characterization. With a broad offering of systems, software and consumables for evaluating binding affinities and protein stability, scientists in pharmaceutical, biotech or academic labs will find an optimized workflow, quality results and responsive customer support. Work with a deeply experienced and globally operating team, and realize the NanoTemper experience.

Neutec Group provides cost effective Instrument and Automation Solutions which enhance the productivity of the Micro and Biotech Labs. Our products are distinguished by innovative design, durability, reliability, and value - the same qualities we look for when selecting partners. We integrate the products we represent with accessories, interface them with computers and printers, and build complete laboratory solutions to meet your specific needs. Some of our products include: Agar & Tube Fillers, Media Preparators, our innovative Spiral Plater, Automatic Colony Counters, Petri Labeler, Water Activity Meters, Multi Spectral imaging texture/color analyzer.

NuProbe takes a multi-platform approach to apply its breakthrough technologies in genomics research to enable diseases to be detected, treated, and cured at early stages for better outcomes with lower costs. Founded in 2016 and building on scientific findings licensed from the Wyss Institute at Harvard and Rice University, NuProbe is a privately held company with facilities in the US (Houston, TX) and China (Shanghai). The company has assembled an executive team of industry veterans, world-renowned scientists, and entrepreneurs.

Simply put, that's our mission: providing innovative cannabis products to all customers. From our sweet-and-sour THC and CBD gummies to our line of affordable inhalers, each packed with pure THC liquid for particulate delivery, we work to help enthusiasts and cannabis patients relax, unwind, and Njoy life.

Nabis is a leading California-based cannabis distributor, specializing in last mile fulfillment and logistics.

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases, and services across the life, physical, chemical and applied sciences and clinical medicine.

Nature Publishing Group (NPG) is a publisher of high impact scientific and medical information in print and online. NPG publishes journals, online databases, and services across the life, physical, chemical and applied sciences and clinical medicine.

Navitar designs, develops and manufactures innovative optical solutions for clients and enterprises across the globe. Solutions include complete optomechanical and optoelectronic assembly and sub-assembly systems. Our products range from high magnification motorized zoom imaging systems to fisheye projection lenses used in a wide variety of industries including Life Sciences, Industrial Imaging, Microscopy and Projection. The key to our success is our consultative approach to solving complex optical problems through inventive design techniques, the precision at which product is assembled, and the efficiency in which projects move through our business units.

The brain is the most complex and least understood organ in the body. NanoSomiX, Inc. is at the forefront in establishing an entirely new class of non-invasive testing to address the need for improved brain analytic tools for research and clinical applications using Brain Derived Exosomes (BDE). We are interested in working collaboratively with researchers worldwide to use our blood-based assay technology to further biomarker exploration in neurodegenerative diseases. Exosomes are extremely small, membrane-bound vesicles produced by cells throughout the body. NanoSomiX is specifically focused on BDEs - exosomes produced by various brain cell populations. A characteristic of BDEs is that they carry brain-produced biomarkers that relate to brain function. With a simple blood draw, pathologic forms or modulation of certain biomarkers can be assessed by our technology. This biomarker assessment can provide needed information about the health and current status of the different brain cell types. Our laboratory is working with both academic researchers and commercial companies to support ongoing research into biomarkers associated with various neurologic diseases and neurotrauma. Much of our contract work involves studies to confirm the detection of specific biomarkers of interest, and to design protocols for diagnostic or monitoring applications. Working within a CLIA laboratory environment, we can provide a blood-based assay that is repeatable, cost effective and fits easily into a routine diagnostic or research environment. Our proprietary exosome isolation technology is covered by a recently granted patent, with 5 additional patent applications in process to cover various aspects of BDE processing and marker application. Using BDEs to explore clinical applications in neurodegenerative diseases is supported by several peer-reviewed publications. We are ready to work with you to help move your important biomarker projects forward.